Inhibition impairment in frontotemporal dementia, amyotrophic lateral sclerosis, and Alzheimer’s disease: clinical assessment and metabolic correlates

被引:0
|
作者
Jordi A. Matías-Guiu
María Nieves Cabrera-Martín
María Valles-Salgado
Teresa Rognoni
Lucía Galán
Teresa Moreno-Ramos
José Luis Carreras
Jorge Matías-Guiu
机构
[1] Universidad Complutense de Madrid,Department of Neurology. Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC)
[2] Universidad Complutense de Madrid,Department of Nuclear Medicine. Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC)
来源
Brain Imaging and Behavior | 2019年 / 13卷
关键词
Inhibition; Executive functioning; Frontotemporal dementia; Alzheimer’s disease; Amyotrophic lateral sclerosis; Hayling test;
D O I
暂无
中图分类号
学科分类号
摘要
The ability to reject an automatic tendency, i.e. inhibition, has been linked to the prefrontal cortex, but its neural underpinnings are still controversial. Neurodegenerative diseases represent an interesting model to explore this issue, given its frequent impairment in these disorders. We investigated the inhibitory impairment and its neural basis using four different tests, which evaluate the presence of inhibitory dysfunction (Stroop test, Hayling test, and two graphical perseveration tests), and assessed their correlation with brain metabolism using 18F-fluorodeoxyglucose positron emission tomography in a group of 76 participants with behavioral variant frontotemporal dementia (bvFTD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and healthy controls (HC). Inhibition impairment was more frequent in bvFTD and AD, than ALS and HC. AD and bvFTD only differed in the strategy used in Hayling test, and the frequency of impairment in graphical perseveration tests. Correlation between inhibition tests was moderate. The Stroop test correlated with several regions of the frontal and parietal lobes, mainly on the left side. Hayling test correlated with almost all regions of the frontal lobe and, especially, with the orbitofrontal cortex. Some differences in the impaired regions in each disease were found. Inhibition ability was mainly impaired in bvFTD and AD, and it correlated with the bilateral frontal lobe metabolism. There were certain particularities according to the specific task and patients evaluated. These dissimilarities may support the concept of inhibition as a multidimensional construct, with the involvement of common and divergent neural mechanisms.
引用
收藏
页码:651 / 659
页数:8
相关论文
共 50 条
  • [41] The relationship between amyotrophic lateral sclerosis and frontotemporal dementia
    George M. Ringholz
    Scott R. Greene
    Current Neurology and Neuroscience Reports, 2006, 6 : 387 - 392
  • [42] CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia
    Kelly L. Williams
    Simon Topp
    Shu Yang
    Bradley Smith
    Jennifer A. Fifita
    Sadaf T. Warraich
    Katharine Y. Zhang
    Natalie Farrawell
    Caroline Vance
    Xun Hu
    Alessandra Chesi
    Claire S. Leblond
    Albert Lee
    Stephanie L. Rayner
    Vinod Sundaramoorthy
    Carol Dobson-Stone
    Mark P. Molloy
    Marka van Blitterswijk
    Dennis W. Dickson
    Ronald C. Petersen
    Neill R. Graff-Radford
    Bradley F. Boeve
    Melissa E. Murray
    Cyril Pottier
    Emily Don
    Claire Winnick
    Emily P. McCann
    Alison Hogan
    Hussein Daoud
    Annie Levert
    Patrick A. Dion
    Jun Mitsui
    Hiroyuki Ishiura
    Yuji Takahashi
    Jun Goto
    Jason Kost
    Cinzia Gellera
    Athina Soragia Gkazi
    Jack Miller
    Joanne Stockton
    William S. Brooks
    Karyn Boundy
    Meraida Polak
    José Luis Muñoz-Blanco
    Jesús Esteban-Pérez
    Alberto Rábano
    Orla Hardiman
    Karen E. Morrison
    Nicola Ticozzi
    Vincenzo Silani
    Nature Communications, 7
  • [43] The role of hnRNPs in frontotemporal dementia and amyotrophic lateral sclerosis
    Bampton, Alexander
    Gittings, Lauren M.
    Fratta, Pietro
    Lashley, Tammaryn
    Gatt, Ariana
    ACTA NEUROPATHOLOGICA, 2020, 140 (05) : 599 - 623
  • [44] Imaging Procedures for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
    Prell, T.
    Grosskreutz, J.
    KLINISCHE NEUROPHYSIOLOGIE, 2013, 44 (02) : 145 - 153
  • [45] FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis
    Mackenzie, Ian R. A.
    Neumann, Manuela
    BRAIN RESEARCH, 2012, 1462 : 40 - 43
  • [46] Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum
    Agarwal, Smriti
    Highton-Williamson, Elizabeth
    Caga, Jashelle
    Matamala, Jose M.
    Dharmadasa, Thanuja
    Howells, James
    Zoing, Margaret C.
    Shibuya, Kazumoto
    Geevasinga, Nimeshan
    Vucic, Steve
    Hodges, John R.
    Ahmed, Rebekah M.
    Kiernan, Matthew C.
    JOURNAL OF NEUROLOGY, 2018, 265 (08) : 1819 - 1828
  • [47] Genetic Testing for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: Impact on Clinical Management
    Roggenbuck, Jennifer
    Fong, Jamie C.
    CLINICS IN LABORATORY MEDICINE, 2020, 40 (03) : 271 - +
  • [48] Alterations to metabolic hormones in amyotrophic lateral sclerosis and frontotemporal dementia postmortem human tissue
    Atkinson, Rachel A. K.
    Collins, Jessica M.
    Sreedharan, Jemeen
    King, Anna E.
    Fernandez-Martos, Carmen M.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2024, 83 (11): : 907 - 916
  • [49] Extracellular vesicles act as disease propagator in amyotrophic lateral sclerosis and frontotemporal dementia
    Trotti, D.
    Cicardi, M. E.
    GLIA, 2021, 69 : E96 - E97
  • [50] Prodromes in demyelinating disorders, amyotrophic lateral sclerosis, Parkinson disease, and Alzheimer's dementia
    Marrie, R. A.
    Maxwell, C. J.
    Rotstein, D. L.
    Tsai, C. -C.
    Tremlett, H.
    REVUE NEUROLOGIQUE, 2024, 180 (03) : 125 - 140